Clive Morris
Keine laufenden Positionen mehr
Profil
Clive Morris worked as a Managing Director at CorpHQ, Inc. He was also an Investor Relations Contact at AstraZeneca PLC and President-Inivata at NeoGenomics, Inc. Morris was a Director at Inivata Ltd.
in 2022.
He holds a doctorate degree from The Royal College of Surgeons of England.
Ehemalige bekannte Positionen von Clive Morris
| Unternehmen | Position | Ende |
|---|---|---|
Inivata Ltd.
 Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Vorstandsvorsitzender | 18.06.2021 |
| NEOGENOMICS, INC. | Corporate Officer/Principal | 30.06.2022 |
| CorpHQ, Inc. | Corporate Officer/Principal | 06.08.2007 |
| ASTRAZENECA PLC | Public Communications Contact | - |
Ausbildung von Clive Morris
| The Royal College of Surgeons of England | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| NEOGENOMICS, INC. | Health Services |
| Private Unternehmen | 2 |
|---|---|
| CorpHQ, Inc. | Communications |
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Technology Services |
